8-K: Cogent Biosciences Reports Highly Positive Phase 2 SUMMIT Trial Results for Bezuclastinib in Non-Advanced Systemic Mastocytosis

Cogent Biosciences, Inc. announced positive top-line results from the registration-directed Part 2 of the SUMMIT clinical trial of bezuclastinib for non-advanced systemic mastocytosis, demonstrating clinically meaningful and highly statistically significant improvements across primary and key secondary endpoints.

Summary

• Positive top-line results were announced from Part 2 of the SUMMIT clinical trial of bezuclastinib in patients with non-advanced systemic mastocytosis (NonAdvSM).
• The trial achieved its primary endpoint with a highly statistically significant difference in the mean change in total symptom score (TSS) at 24 weeks (p=0.0002).
• The bezuclastinib arm showed a mean reduction of 24.3 points in TSS at 24 weeks, compared to a mean reduction of 15.4 points in the placebo arm, resulting in a placebo-adjusted TSS improvement of 8.91 points.
• Highly statistically significant benefit was demonstrated across all key secondary endpoints, including a >50% reduction in serum tryptase in 87.4% of bezuclastinib-treated patients versus 0% in the control arm (p<0.0001).
• Other statistically significant secondary endpoints included >50% reduction in KIT D816V VAF (p<0.0001), >50% reduction in TSS (p=0.0142), >50% reduction in Bone Marrow MC Aggregates (p<0.0001), >30% reduction in TSS (p=0.0004), and mean change in Most Severe Symptom at Baseline (p=0.0001).
• The majority of treatment emergent adverse events (TEAEs) were of low grade (98.3% in bezuclastinib arm vs. 88.3% in placebo arm).
• Serious adverse events occurred in 4.2% of patients treated with bezuclastinib, compared to 5.0% of patients treated with placebo.
• Discontinuations due to treatment-related adverse events occurred in 5.9% of patients treated with bezuclastinib, all due to ALT/AST elevations which fully resolved.

Sentiment

Score: 9

Explanation: The document reports highly positive and statistically significant top-line results from a registration-directed clinical trial, meeting all primary and key secondary endpoints with a favorable safety profile. This positions the company for an NDA submission and represents a major de-risking event for the drug candidate.

Positives

• Bezuclastinib achieved clinically meaningful and highly statistically significant improvements across the primary and all key secondary endpoints in the SUMMIT trial for NonAdvSM.
• The primary endpoint, mean change in TSS at 24 weeks, was met with a p-value of 0.0002, demonstrating an 8.91-point placebo-adjusted improvement.
• All key secondary endpoints, including significant reductions in serum tryptase (87.4% vs. 0% for placebo), KIT D816V VAF, and bone marrow mast cell aggregates, showed highly statistically significant benefits.
• The safety and tolerability profile of bezuclastinib appears favorable, with 98.3% of treatment emergent adverse events being low grade.
• Serious adverse events were slightly lower in the bezuclastinib arm (4.2%) compared to placebo (5.0%).
• Discontinuations due to treatment-related adverse events were low (5.9%) and were attributed to manageable ALT/AST elevations that fully resolved, with no other hepatic adverse events reported.
• The company is on track to submit its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvSM by the end of 2025.

Negatives

• The most frequent treatment emergent adverse events reported on bezuclastinib treatment included hair color change (69.5% vs. 5.0% placebo), altered taste (23.7% vs. 0% placebo), nausea (22.0% vs. 13.3% placebo), and alanine transaminase (ALT)/aspartate transaminase (AST) elevations (22.0% vs. 6.6% placebo; >Gr 3, 5.9% vs. 0%). While mostly low grade, these are notable side effects.

Risks

• Forward-looking statements are subject to a number of material risks and uncertainties, including those set forth under the caption Risk Factors in the company's most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q, and subsequent filings with the Securities and Exchange Commission.
• The company may not actually achieve the forecasts or milestones disclosed in its forward-looking statements.
• New risks and uncertainties may emerge from time to time, and it is not possible to predict all such risks and uncertainties.

Future Outlook

The company expects to submit its first New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvSM by the end of 2025. Detailed results from the SUMMIT trial are planned for presentation at an upcoming major medical conference later this year. Additionally, top-line results from the Phase 3 PEAK trial (bezuclastinib in combination with sunitinib in gastrointestinal stromal tumors) and the registration-directed APEX trial (bezuclastinib in advanced systemic mastocytosis patients) are anticipated during the second half of 2025. The company believes bezuclastinib has the potential to become a new standard of care for patients with NonAdvSM and that its safety and tolerability profile supports chronic dosing.

Management Comments

• The Company is on track to submit its first new drug application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvSM by the end of 2025.
• The Company plans to present detailed results from the SUMMIT trial at an upcoming medical meeting later this year.
• The Company remains on track to provide top-line results from both PEAK, a Phase 3 trial of bezuclastinib in combination with sunitinib in patients with gastrointestinal stromal tumors, and APEX, a registration-directed trial of bezuclastinib in advanced systemic mastocytosis patients, during the second half of 2025.

Industry Context

The positive results for bezuclastinib in non-advanced systemic mastocytosis position Cogent Biosciences as a potential leader in developing targeted therapies for rare diseases, particularly those driven by KIT D816V mutations. Systemic mastocytosis is a rare and debilitating disease with significant unmet medical needs, and a new, effective oral therapy could significantly impact patient care and market dynamics. The successful trial outcome could strengthen Cogent's competitive standing against other companies developing mastocytosis treatments.

Comparison to Industry Standards

• The document does not provide specific comparable companies, projects, or results to benchmark against. However, the statistically significant improvements across primary and all key secondary endpoints, including patient-reported symptoms and objective measures of mast cell burden, suggest a strong clinical profile for bezuclastinib in NonAdvSM.
• The safety profile, with a majority of low-grade adverse events and a low discontinuation rate due to treatment-related issues (5.9%), appears favorable, especially given the chronic nature of systemic mastocytosis, where long-term tolerability is crucial.

Stakeholder Impact

• Shareholders: Positive trial results and progress towards NDA submission are highly likely to increase investor confidence and potentially the company's valuation.
• Patients: Bezuclastinib could offer a new, effective, and well-tolerated treatment option for non-advanced systemic mastocytosis, potentially improving quality of life and disease management.
• Healthcare Providers: The drug could become a new standard of care, providing a valuable tool for treating NonAdvSM.
• Regulators (FDA): The positive data will be reviewed as part of the NDA submission process.

Next Steps

• Submit New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for bezuclastinib in NonAdvSM by the end of 2025.
• Present detailed results from the SUMMIT trial at an upcoming major medical conference later in 2025.
• Provide top-line results from the PEAK Phase 3 trial (bezuclastinib + sunitinib in GIST) during the second half of 2025.
• Provide top-line results from the APEX registration-directed trial (bezuclastinib in advanced systemic mastocytosis) during the second half of 2025.
• Complete analysis of the full SUMMIT Part 2 data.

Key Dates

Recommendation

Keywords

Cogent Biosciences, bezuclastinib, SUMMIT trial, non-advanced systemic mastocytosis, NonAdvSM, clinical trial results, Phase 2, FDA, NDA, drug development, rare disease, mastocytosis, biotechnology, pharmaceuticals, oncology, KIT D816V, serum tryptase, TSS